Literature DB >> 8584620

Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.

J Fang1, D Zuo, P H Yu.   

Abstract

Haloperidol has recently been found to be metabolized to its pyridinium ion (HP+). This conversion of haloperidol to HP+ appears to be similar to the activation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to N-methyl-4-phenyl pyridinium ion (MPP+). MPP+ is responsible for the damage of striatal dopaminergic neurons induced by MPTP in humans and animals. It seemed sensible to investigate whether or not HP+ might be toxic towards dopaminergic neurons and perhaps associated with some of the residual moto-function side effects of haloperidol. We therefore investigated the neurotoxicity of HP+ toward cultured human dopamine neuroblastoma cells (SH-SY5Y) and compared it with that of MPP+. HP+ reduced the viability as measured by MTT and [3H]thymidine incorporation methods in SH-SY5Y cells. Cell membrane integrity is reduced by the treatment of HP+ as measured by intracellular LDH levels. The toxicity was concentration and time dependent. Interestingly, HP+ appeared to be more toxic than MPP+ towards the SH-SY5Y cells in early phase in cultures. The toxicity of MPP+ appear to be progressive and subsequently become more than HP+ with prolonged cultivation. In contrary to MPP+, the toxic effect of HP+ towards a dopamine transporter transfected SK-N-MC cell line is not different from its wild type. This indicates that dopamine uptake system is probably not involved in the cytotoxicity caused by HP+.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8584620     DOI: 10.1007/bf02246077

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

Review 1.  Dopamine receptors and the dopamine hypothesis of schizophrenia.

Authors:  P Seeman
Journal:  Synapse       Date:  1987       Impact factor: 2.562

2.  Synaptic changes in the rabbit pallidum following long-term haloperidol administration.

Authors:  J Koizumi; H Shiraishi
Journal:  Folia Psychiatr Neurol Jpn       Date:  1973

3.  Effect of nerve growth factor on catecholamine metabolism in a human neuroblastoma clone (SY5Y).

Authors:  J R Perez-Polo; E Tiffany-Castiglioni; M G Ziegler; K Werrbach-Perez
Journal:  Dev Neurosci       Date:  1982       Impact factor: 2.984

4.  3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.

Authors:  J Kornhuber; P Riederer; G P Reynolds; H Beckmann; K Jellinger; E Gabriel
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

5.  High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations.

Authors:  J Fang; J W Gorrod
Journal:  J Chromatogr       Date:  1993-05-05

6.  Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection.

Authors:  K Igarashi; N Castagnoli
Journal:  J Chromatogr       Date:  1992-09-02

7.  Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.

Authors:  C Pifl; B Giros; M G Caron
Journal:  J Neurosci       Date:  1993-10       Impact factor: 6.167

8.  Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP.

Authors:  R R Ramsay; J Dadgar; A Trevor; T P Singer
Journal:  Life Sci       Date:  1986-08-18       Impact factor: 5.037

9.  One year of continuous treatment with haloperidol or clozapine fails to induce a hypersensitive response of caudate putamen neurons to dopamine D1 and D2 receptor agonists.

Authors:  L H Jiang; R J Kasser; C A Altar; R Y Wang
Journal:  J Pharmacol Exp Ther       Date:  1990-06       Impact factor: 4.030

Review 10.  MPTP toxicity: implications for research in Parkinson's disease.

Authors:  I J Kopin; S P Markey
Journal:  Annu Rev Neurosci       Date:  1988       Impact factor: 12.449

View more
  9 in total

1.  Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.

Authors:  Kwakye Peprah; Xue Y Zhu; Suresh V K Eyunni; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2011-12-22       Impact factor: 3.641

2.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

3.  Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.

Authors:  J Fang; G B Baker; P H Silverstone; R T Coutts
Journal:  Cell Mol Neurobiol       Date:  1997-04       Impact factor: 5.046

4.  Binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a metabolite of haloperidol, to synthetic melanin: implications for the dopaminergic neurotoxicity of HPP+.

Authors:  Hidekazu Kawashima; Yasuhiko Iida; Youji Kitamura; Hideo Saji
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 5.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

6.  Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.

Authors:  Seth Y Ablordeppey; Ramazan Altundas; Barbara Bricker; Xue Y Zhu; Eyunni V K Suresh Kumar; Tanise Jackson; Abdul Khan; Bryan L Roth
Journal:  Bioorg Med Chem       Date:  2008-06-20       Impact factor: 3.641

7.  Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice.

Authors:  James J Crowley; Mehdi Ashraf-Khorassani; Neal Castagnoli; Patrick F Sullivan
Journal:  Neurotoxicology       Date:  2013-10-06       Impact factor: 4.294

8.  Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations.

Authors:  Etsuko Usuki; Jeffrey R Bloomquist; Ethan Freeborn; Kay Casagnoli; Cornelis J Van Der Schyf; Neal Castagnoli
Journal:  Neurotox Res       Date:  2002-02       Impact factor: 3.911

9.  Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.

Authors:  Steven P Presgraves; Tariq Ahmed; Sabine Borwege; Jeffrey N Joyce
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.978

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.